Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors or Lymphomas”

272 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 272 results

Early research (Phase 1)Active Not RecruitingNCT03502733
What this trial is testing

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Who this might be right for
LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 64
Very early researchEnded earlyNCT03454243
What this trial is testing

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Hoffmann-La Roche 1
Not applicableLooking for participantsNCT06073938
What this trial is testing

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Who this might be right for
Advanced Solid Tumors or Lymphomas
Hunan Province Tumor Hospital 30
Early research (Phase 1)Study completedNCT01032681
What this trial is testing

EMD 521873 in Advanced Solid Tumors, MTD Finding

Who this might be right for
Non-Hodgkin Lymphoma
Merck KGaA, Darmstadt, Germany 66
Early research (Phase 1)Study completedNCT00646139
What this trial is testing

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Who this might be right for
LymphomaLymphoproliferative DisorderSmall Intestine Cancer+1 more
Roswell Park Cancer Institute 7
Early research (Phase 1)Study completedNCT05564806
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed Or Refractory Non-Hodgkin Lymphoma
Eucure (Beijing) Biopharma Co., Ltd 9
Early research (Phase 1)Study completedNCT00004065
What this trial is testing

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Who this might be right for
Bladder CancerBreast CancerColorectal Cancer+9 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT02812875
What this trial is testing

CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Who this might be right for
Advanced Solid Tumors or Lymphomas
Curis, Inc. 71
Early research (Phase 1)Study completedNCT00060645
What this trial is testing

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 33
Early research (Phase 1)Study completedNCT01898078
What this trial is testing

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

Who this might be right for
Advanced Solid TumorsLymphoma
Millennium Pharmaceuticals, Inc. 26
Early research (Phase 1)Study completedNCT03010176
What this trial is testing

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Who this might be right for
Solid TumorsLymphoma
Merck Sharp & Dohme LLC 156
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Ended earlyNCT03648372
What this trial is testing

TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Who this might be right for
NeoplasmsLymphomaHematologic Neoplasms
Takeda 109
Early research (Phase 1)Study completedNCT02392611
What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Who this might be right for
Solid Tumors and Lymphomas
Gilead Sciences 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390865
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 49
Testing effectiveness (Phase 2)Study completedNCT01897571
What this trial is testing

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Who this might be right for
B-cell Lymphomas (Phase 1)Advanced Solid Tumors (Phase 1)Diffuse Large B-cell Lymphoma (Phase 2)+3 more
Epizyme, Inc. 400
Early research (Phase 1)UnknownNCT05415098
What this trial is testing

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Who this might be right for
Nasopharyngeal CarcinomaCastrate Resistant Prostate CancerGastric Cancer+6 more
Ascentage Pharma Group Inc. 90
Testing effectiveness (Phase 2)Study completedNCT02273739
What this trial is testing

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Who this might be right for
Solid TumorGliomaAngioimmunoblastic T-cell Lymphoma+2 more
Celgene 21
Early research (Phase 1)Ended earlyNCT06028373
What this trial is testing

ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Who this might be right for
Advanced Solid TumorsB-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited 38
Not applicableStudy completedNCT02054741
What this trial is testing

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

Who this might be right for
Adult Solid NeoplasmToxicityLymphoma
Supriya Mohile 733
Next Page